HD-tDCS + Language Therapy for Primary Progressive Aphasia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether combining language therapy with a non-invasive brain stimulation technique, high-definition transcranial direct current stimulation (HD-tDCS), can improve language skills in individuals with Primary Progressive Aphasia (PPA), a condition affecting language abilities and quality of life. Researchers are particularly interested in whether stimulating different brain areas can enhance both language and cognitive functions. Participants with PPA who are right-handed, proficient in English, and have at least a high-school education may be eligible to join. The trial will alternate between real and sham (placebo-like) stimulation to assess effectiveness. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could enhance language and cognitive functions for those with PPA.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this method is safe for treating language deficits in primary progressive aphasia?
Research shows that high-definition transcranial direct current stimulation (HD-tDCS) is generally safe. Studies suggest that this brain stimulation can be a safe and possibly effective treatment, especially when combined with language therapy for conditions like primary progressive aphasia. Some people report mild side effects, such as tingling or itching on the scalp, but these are usually temporary and not serious. Overall, when used as part of a structured therapy plan, research has not identified any major safety concerns with HD-tDCS.12345
Why are researchers excited about this trial?
Researchers are excited about HD-tDCS for Primary Progressive Aphasia because it offers a new way to stimulate the brain. Unlike traditional speech therapy alone, HD-tDCS uses a non-invasive brain stimulation technique that can enhance language therapy by targeting specific brain regions involved in language processing. This approach has the potential to improve language abilities more effectively and quickly than current methods, offering hope for better outcomes in individuals with this challenging condition.
What evidence suggests that HD-tDCS combined with language therapy could be effective for primary progressive aphasia?
Research has shown that high-definition transcranial direct current stimulation (HD-tDCS) can significantly enhance language skills in individuals with primary progressive aphasia (PPA). Studies have found that HD-tDCS, particularly when applied to critical language areas in the brain, improves abilities such as word fluency and spelling. Specifically, stimulating the left inferior frontal gyrus (LIFG), a key language area, has led to noticeable improvements. This trial will compare two treatment sequences: one where participants first receive active HD-tDCS with language/cognitive interventions, and another where they first receive Sham with language/cognitive interventions. This treatment also appears to enhance connectivity and communication between different brain regions, potentially extending language improvements to other tasks. Overall, evidence suggests that HD-tDCS is a promising method for enhancing language functions in PPA.12356
Who Is on the Research Team?
Kyrana Tsapkini, PhD
Principal Investigator
Johns Hopkins University
Are You a Good Fit for This Trial?
This trial is for right-handed individuals aged 50-80 with Primary Progressive Aphasia or dementia, who have completed at least high school and are proficient in English. They must be diagnosed at specialized clinics based on consensus criteria. Healthy controls matched by age and education may also participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Sham or active HD-tDCS combined with Language/Cognitive Interventions
Washout
A washout period between crossover phases to eliminate carryover effects
Follow-up
Participants are monitored for changes in language and cognitive functions post-intervention
What Are the Treatments Tested in This Trial?
Interventions
- High-definition active tDCS (HD-tDCS)
- Sham
High-definition active tDCS (HD-tDCS) is already approved in United States for the following indications:
- Investigational use in clinical trials for logopenic variant primary progressive aphasia (lvPPA)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Institute on Aging (NIA)
Collaborator